Charles Meno Theodore DeBoer

Dr. Charles Meno Theodore DeBoer

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2019 in Ophthalmology Glaucoma
Verified
Journal Article
Closed access
BXBenjamin Xu
Benjamin Xu
APAnmol A. Pardeshi
Anmol A. Pardeshi
JSJing Shan
Jing Shan
CDCharles Meno Theodore DeBoer
Charles Meno Theodore DeBoer
SMSasan Moghimi
Sasan Moghimi
RVRohit Varma
Rohit Varma

20 March 2023 in Current Opinion in Ophthalmology
Verified
Journal Article
Closed access
CDCharles Meno Theodore DeBoer
Charles Meno Theodore DeBoer
RARajat Agrawal
Rajat Agrawal
EREhsan Rahimy
Ehsan Rahimy
Purpose of review: Intravitreal and periocular injections for retinal disease provide a targeted delivery of medication to the eye. However, given risks of injections, including endophthalmitis, pain and treatment burden for both patients and retina specialists, there has been significant interest and effort in developing oral medications for the management of retinal disease. This article provides clinical and preclinical details of new oral medications in the pipeline for management of retinal disease. Recent findings: Several new oral medications show clinical and preclinical promise for the management of retinal disease, including macular degeneration, diabetic retinopathy and Stargardt disease. Summary: Oral medications provide promise for treating retinal disease, possibly increasing compliance, and reducing side effects of intravitreal or periocular injections. However, difficulties in this approach include systemic side effects and efficacy targeting the eye. There are multiple medications that are currently under investigation with the potential to act as stand-alone treatment or as an adjunct treatment for management of retinal diseases such as diabetic retinopathy, macular degeneration and Stargardt disease.

26 September 2025 in Current Ophthalmology Reports
Verified
Journal Article
Open access
PDF file
HKHyeonji Kim
Hyeonji Kim
GNGia-Han Ngo
Gia-Han Ngo
WHWen Hong
Wen Hong
SLSoo Hyeon Lee
Soo Hyeon Lee
VMVinit B. Mahajan
Vinit B. Mahajan
CDCharles Meno Theodore DeBoer
Charles Meno Theodore DeBoer
Purpose of Review In this article, we provide a brief overview of 3D bioprinting technologies and the types of cells employed in ophthalmic cell therapy. We then explore recent applications of 3D bioprinting in ophthalmic cell delivery systems. Recent Findings Cell therapy in ophthalmology is a promising treatment for various eye diseases, there exists some limitations of existing cell therapy strategies Such as cell loss, poor integration with Surrounding tissues, and the sustainability of long-term effects. In this regard, 3D bioprinting technology provides a beneficial method for developing highly biomimetic and reliable cell delivery systems for ophthalmic disease research. Recent advances have shown bioengineered tissues which replicate the microstructure of native tissues, personalized ophthalmic devices, and encapsulated cell-delivery systems. While still in the early stages of advancement, the development of cell delivery systems based on bioprinting technologies is indeed inspiring and has the potential to be applied to other ocular diseases. Summary Cell therapy based on 3D bioprinting technology in ophthalmology has great potential in ophthalmic disease treatment as well as ocular tissue engineering and regenerative medicine.

21 July 2024 in Vision
Verified
Journal Article
Open access
PDF file
CZCindy S Zhao
Cindy S Zhao
KWKaren Wai
Karen Wai
EKEubee Koo
Eubee Koo
EREhsan Rahimy
Ehsan Rahimy
PMPrithvi Mruthyunjaya
Prithvi Mruthyunjaya
CDCharles Meno Theodore DeBoer
Charles Meno Theodore DeBoer
Purpose: We aim to present a case of disseminated fusariosis that occurred in the setting of immunosuppression and presented with bilateral endogenous endophthalmitis, along with a literature review of Fusarium endophthalmitis, highlighting management strategies. Observation: A 70-year-old male with acute myeloid leukemia who had recently undergone a bone marrow transplant noted bilateral floaters and decreased vision. He was found to have bilateral Fusarium endophthalmitis, with subsequent evidence of fungemia and fusariosis in his skin and joints. Despite aggressive local and systemic treatment, he succumbed to the disease. Endophthalmitis was initially stabilized with pars plana vitrectomy and intravitreal amphotericin and voriconazole until the patient transitioned to comfort measures. A review of 31 cases demonstrates that outcomes are poor and that the disease must be treated aggressively, often both systemically and surgically. Conclusion: This case highlights the recalcitrance of Fusarium bacteremia and Fusarium endophthalmitis.

7 May 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
HKHyeonji Kim
Hyeonji Kim
NKNae-Won Kang
Nae-Won Kang
RWRoger Wise
Roger Wise
AFAkira Feliz
Akira Feliz
DMDavid Myung
David Myung
CDCharles Meno Theodore DeBoer
Charles Meno Theodore DeBoer

17 October 2024 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
BSBrian T. Soetikno
Brian T. Soetikno
HGHashem Ghoraba
Hashem Ghoraba
ABArthur Brant
Arthur Brant
CDCharles Meno Theodore DeBoer
Charles Meno Theodore DeBoer
LGLucie Guo
Lucie Guo
MHMary Hartnett
Mary Hartnett
To report a case of neovascular glaucoma in an 8-year-old male, secondary to a racemose hemangioma without associated intracranial arteriovenous malformation, highlighting the challenges in management and novel findings on optical coherence tomography angiography (OCTA). An 8-year-old male initially presented with pain, redness, and blurred vision in the right eye. The patient was diagnosed with secondary neovascular glaucoma due to a racemose hemangioma. Urgent interventions included intravitreal bevacizumab injection and tube shunt surgery for persistently high intraocular pressure. Pars plana vitrectomy and scatter laser photocoagulation were eventually performed to manage a tractional retinal detachment and peripheral ischemia, respectively. OCTA imaging revealed a racemose hemangioma with a unique chorioretinal anastomosis. We present a rare pediatric case of neovascular glaucoma secondary to a racemose hemangioma with significant peripheral ischemia and an unusual chorioretinal anastomosis. The discovery of a chorioretinal anastomosis on OCTA suggests a potentially severe variant of racemose hemangioma.